Biogen (BIIB) is set to report fourth-quarter earnings before the bell Friday, with Wall Street anticipating a year-over-year revenue decline. The results come amid a mixed landscape for biotechnology peers and broader economic uncertainties.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
While Cannara Biotech (CVE:LOVE) reported impressive profit growth, a closer look reveals shareholder dilution is tempering per-share gains and may be weighing on the stock's performance.
Sotera Health's stock presents a valuation conundrum, with discounted cash flow analysis suggesting a 37% upside while its sky-high P/E ratio signals overvaluation. As investors reassess biotech and pharmaceutical services firms, the debate intensifies around SHC's true worth.
Eikon Therapeutics, a biotech firm founded by Nobel laureate Eric Betzig, raised $381.2 million in its Nasdaq debut, pricing shares at $18. The offering signals renewed investor confidence in the biotech IPO market after a prolonged slowdown.
Clinical research giant IQVIA (NYSE: IQV) is scheduled to release its fourth-quarter financial results before Thursday's market open. With a track record of consistently topping revenue estimates, the report will be closely watched for signs of resilience in the life sciences tools and services sector.
Veradermics Inc., a clinical-stage biopharmaceutical company developing a novel treatment for pattern hair loss, priced its IPO above expectations, raising $256.3 million and achieving a market valuation of nearly $600 million. The offering signals renewed investor appetite for biotech listings.
Giverny Capital has spotlighted Medpace Holdings' aggressive share repurchase program as a vote of confidence, as the contract research organization navigates persistent concerns over biopharmaceutical funding. The firm's strategy highlights a broader debate on capital allocation in a volatile sector.
Recent volatility in Genscript Biotech's (SEHK:1548) share price has investors questioning its true worth. While short-term gains offer a glimmer, a deeper look reveals a stark three-year decline, setting the stage for a critical valuation debate.
Arcellx (ACLX) shares are caught in a tug-of-war between conflicting valuation signals. While a sky-high price-to-book ratio suggests the stock is richly valued, a discounted cash flow model implies massive upside potential. We examine the data behind the biotech's recent price swings and what investors are really betting on.
Investment firm Hussman Strategic Advisors has liquidated its entire stake in TG Therapeutics, a move that comes as the biotech's stock lags behind broader market gains despite reporting strong revenue growth for its flagship product.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
Morgan Stanley has secured the leading position as a financial adviser for mergers and acquisitions in the global power sector for 2025, advising on deals worth a combined $63.4 billion, according to new industry data.
New federal data reveals a cooldown in Nevada's labor market, with job openings declining in November. While hiring continues, particularly in northern industries, the slowdown in Las Vegas's leisure and hospitality sector signals a shift as employers adopt a more cautious stance.
As the earnings season wraps up, regional banks demonstrated surprising strength in the third quarter. While facing headwinds from fintech competition and commercial real estate concerns, institutions like Stock Yards Bank posted record results, signaling cautious optimism for the sector.
While the industrial sector has outperformed the broader market, buoyed by regulatory tailwinds, analysts warn that selective caution is warranted. We examine three companies where valuation concerns and cyclical risks suggest investors should tread carefully.
An analysis of Q4 earnings reveals a sector cautiously optimistic. While facing challenges from fintech and commercial real estate, regional banks like Camden National Bank posted solid results, with the tracked group beating revenue estimates by 1.4% on average.
